JP7773730B2 - miR-33b阻害物質による動脈瘤の予防または治療 - Google Patents

miR-33b阻害物質による動脈瘤の予防または治療

Info

Publication number
JP7773730B2
JP7773730B2 JP2022504376A JP2022504376A JP7773730B2 JP 7773730 B2 JP7773730 B2 JP 7773730B2 JP 2022504376 A JP2022504376 A JP 2022504376A JP 2022504376 A JP2022504376 A JP 2022504376A JP 7773730 B2 JP7773730 B2 JP 7773730B2
Authority
JP
Japan
Prior art keywords
mir
modified
antisense oligonucleotide
oligonucleotide
amna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022504376A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021177267A1 (cg-RX-API-DMAC7.html
Inventor
淳 小寺
亘 尾野
貴裕 堀江
智弘 山▲崎▼
智史 小山
聡 小比賀
勇矢 笠原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Kyoto University
National Institute of Biomedical Innovation, Health and Nutrition
The University of Osaka
Original Assignee
Kowa Co Ltd
Osaka University NUC
Kyoto University
National Institute of Biomedical Innovation, Health and Nutrition
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd, Osaka University NUC, Kyoto University, National Institute of Biomedical Innovation, Health and Nutrition filed Critical Kowa Co Ltd
Publication of JPWO2021177267A1 publication Critical patent/JPWO2021177267A1/ja
Application granted granted Critical
Publication of JP7773730B2 publication Critical patent/JP7773730B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022504376A 2020-03-02 2021-03-02 miR-33b阻害物質による動脈瘤の予防または治療 Active JP7773730B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020034619 2020-03-02
JP2020034619 2020-03-02
PCT/JP2021/007822 WO2021177267A1 (ja) 2020-03-02 2021-03-02 miR-33b阻害物質による動脈瘤の予防または治療

Publications (2)

Publication Number Publication Date
JPWO2021177267A1 JPWO2021177267A1 (cg-RX-API-DMAC7.html) 2021-09-10
JP7773730B2 true JP7773730B2 (ja) 2025-11-20

Family

ID=77613063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022504376A Active JP7773730B2 (ja) 2020-03-02 2021-03-02 miR-33b阻害物質による動脈瘤の予防または治療

Country Status (7)

Country Link
US (1) US20230159924A1 (cg-RX-API-DMAC7.html)
EP (1) EP4129338A4 (cg-RX-API-DMAC7.html)
JP (1) JP7773730B2 (cg-RX-API-DMAC7.html)
CN (1) CN116096420B (cg-RX-API-DMAC7.html)
AR (1) AR121490A1 (cg-RX-API-DMAC7.html)
TW (1) TW202146651A (cg-RX-API-DMAC7.html)
WO (1) WO2021177267A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4331606A4 (en) * 2021-04-30 2025-05-07 Kyoto University PREVENTION OR TREATMENT OF MYOPATHY USING A MIR-33B INHIBITOR
WO2022260162A1 (ja) * 2021-06-11 2022-12-15 国立大学法人京都大学 Nashの予防及び/又は治療剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532392A (ja) 2006-04-03 2009-09-10 サンタリス ファーマ アー/エス antimiRNAアンチセンスオリゴヌクレオチドを含む医薬組成物
JP2012522509A (ja) 2009-03-31 2012-09-27 ザ ジェネラル ホスピタル コーポレイション コレステロール関連障害の治療におけるmir−33マイクロrnaの調節

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
DE602007009487D1 (de) 2006-01-27 2010-11-11 Isis Pharmaceutical Inc 6-modifizierte bicyclische nukleinsäureanaloga
DK2170917T3 (da) 2007-05-30 2012-10-08 Isis Pharmaceuticals Inc N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
AU2010312751B2 (en) 2009-10-29 2014-07-24 Osaka University Bridged artificial nucleoside and nucleotide
WO2012027601A2 (en) * 2010-08-25 2012-03-01 The General Hospital Corporation Methods targeting mir-33 micrornas for regulating lipid metabolism

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532392A (ja) 2006-04-03 2009-09-10 サンタリス ファーマ アー/エス antimiRNAアンチセンスオリゴヌクレオチドを含む医薬組成物
JP2012522509A (ja) 2009-03-31 2012-09-27 ザ ジェネラル ホスピタル コーポレイション コレステロール関連障害の治療におけるmir−33マイクロrnaの調節

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Arterioscler Thromb Vasc Biol.,2018年07月26日,Vol. 2018 No, 38,p. 2460-2473, suppl.
Perfusion,2019年06月06日,Vol. 35, No. 1,p. 57-65

Also Published As

Publication number Publication date
EP4129338A1 (en) 2023-02-08
EP4129338A4 (en) 2024-04-10
CN116096420A (zh) 2023-05-09
JPWO2021177267A1 (cg-RX-API-DMAC7.html) 2021-09-10
AR121490A1 (es) 2022-06-08
WO2021177267A1 (ja) 2021-09-10
TW202146651A (zh) 2021-12-16
US20230159924A1 (en) 2023-05-25
CN116096420B (zh) 2026-07-17

Similar Documents

Publication Publication Date Title
JP2022078069A (ja) 二本鎖RNAによるα-1アンチトリプシンの特異的阻害のための方法及び組成物
AU2012322788B2 (en) Micrornas in neurodegenerative disorders
JP2022008677A (ja) アンジオテンシノーゲンの発現を調節するための化合物及び方法
AU2014360314B2 (en) Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
EP3715457A2 (en) Modulation of prekallikrein (pkk) expression
JP2024091781A (ja) Scn1a脳症の治療のためのscn2aを標的とするアンチセンスオリゴヌクレオチド
TW201723176A (zh) Kras表現之調節劑
EP3037538A1 (en) Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
CN105637090A (zh) 用于调节c9orf72表达的组合物
TW201819397A (zh) 減少atxn3表現之化合物及方法
EP2683411B1 (en) Methods of using microrna-26a to promote angiogenesis
TWI840345B (zh) Irf4表現之調節劑
AU2013256471A1 (en) Organic compositions to treat KRAS-related diseases
AU2023208539A1 (en) Compositions and methods for inhibiting complement factor b
CN113710283A (zh) 用于调节dux4的表达的化合物、方法和医药组合物
JP2025156522A (ja) 修飾ヘテロ核酸
EP4129338A1 (en) Prevention or treatment of aneurysms using mir-33b inhibitor
WO2021157730A1 (ja) 核酸医薬とその使用
JP2021534759A (ja) Microrna−134バイオマーカー
JP2023036061A (ja) miR-33b阻害物質による動脈瘤の予防または治療
JP2023130528A (ja) Plp1発現を調節するための化合物、方法及び医薬組成物
EP4331606A1 (en) Prevention or treatment of myopathy using mir-33b inhibitor
JP7776420B2 (ja) Ataxin 3発現を調節するための化合物、方法及び医薬組成物
JP2024089860A (ja) Zic5発現を調節するための核酸複合体
WO2026018824A1 (ja) 核酸医薬とその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240304

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250626

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250722

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251030

R150 Certificate of patent or registration of utility model

Ref document number: 7773730

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150